echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > FDA approves nuclide conjugate drugs for prostate cancer diagnosis!

    FDA approves nuclide conjugate drugs for prostate cancer diagnosis!

    • Last Update: 2021-12-24
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On December 20th, Telix Pharmaceuticals announced that the FDA approved Illuccix (TLX591-CDx) for the marketing of prostate cancer diagnostic imaging
    .

    TLX591-CDx is a diagnostic positron emission tomography (PET) tracer targeting prostate specific membrane antigen (PSMA) based on radionuclide-antibody coupling technology (RDC), suitable for metastatic prostate cancer And the diagnosis of recurrent prostate cancer
    .
    TLX591-CDx has been approved for listing in Australia on November 2, 2021, and is also preparing to submit listing applications to the European Union and Canada

    .

    The National Comprehensive Cancer Network (National Comprehensive Cancer Network) prostate cancer guidelines (2020 edition) recommends TLX591-CDx as a new PET tracer.
    Compared with other approved tracers, it is effective in detecting recurrence in patients with low PSA levels.
    Better

    .
    In addition, PSMA imaging has been included in the clinical practice guidelines of the United States and Europe, which fully reflects the superiority of PSMA imaging, which also laid the foundation for the future market promotion of TLX591-CDx

    .

    In November 2020, Grand Pharmaceuticals signed a cooperation agreement with Telix, and obtained a number of first in class tumor diagnostics (TLX250-CDx, TLX599-CDx) and treatments (TLX591, TLX250, TLX101), including TLX591-CDx, in one fell swoop The exclusive commercialization rights of global innovative RDC products in Greater China (including Hong Kong, Macau, Taiwan), and the company with the largest number of therapeutic + diagnostic RDC drugs in China
    .

    Prostate cancer is one of the most common male cancers.
    According to "Globalcan 2020" data, the global incidence of prostate cancer will exceed 1.
    4 million in 2020, and the death toll will exceed 370,000

    .
    There are more than 110,000 cases of prostate cancer in China, and more than 50,000 deaths

    .
    The incidence rate is increasing year by year

    .
    Due to limited treatment options for metastatic prostate cancer, the 5-year survival rate of Chinese patients is significantly lower than that of the United States

    .
    For prostate cancer patients who resist recurrence and metastasis, there is still a huge clinical need for accurate diagnosis and treatment

    .

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.